Hikma Pharmaceuticals Plc (HIK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | -144,000 | -24,000 | 4,000 | -166,000 | -47,000 |
| Other Working Capital | -135,000 | 80,000 | -131,000 | -30,000 | -208,000 |
| Other Operating Activity | 843,000 | 681,000 | 657,000 | 834,000 | 719,000 |
| Operating Cash Flow | $564,000 | $737,000 | $530,000 | $638,000 | $464,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -165,000 | -151,000 | -137,000 | -145,000 | -172,000 |
| Net Acquisitions | -162,000 | -105,000 | -380,000 | -17,000 | -60,000 |
| Purchase Of Investment | -2,000 | -27,000 | -15,000 | -3,000 | -5,000 |
| Sale Of Investment | 0 | 1,000 | 0 | 6,000 | 2,000 |
| Purchase Sale Intangibles | -70,000 | -35,000 | -78,000 | -84,000 | -52,000 |
| Other Investing Activity | 18,000 | -16,000 | 12,000 | 5,000 | 4,000 |
| Investing Cash Flow | $-381,000 | $-333,000 | $-607,000 | $-238,000 | $-283,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -24,000 | -30,000 | 17,000 | -48,000 | 63,000 |
| Debt Issued | 684,000 | 778,000 | 1,401,000 | 10,000 | 1,543,000 |
| Debt Repayment | -536,000 | -841,000 | -962,000 | -45,000 | -1,372,000 |
| Common Stock Issued | -38,000 | N/A | N/A | N/A | N/A |
| Common Stock Repurchased | N/A | 0 | -300,000 | 0 | -375,000 |
| Dividend Paid | -175,000 | -137,000 | -125,000 | -120,000 | -109,000 |
| Other Financing Activity | -99,000 | -107,000 | -89,000 | -84,000 | -48,000 |
| Financing Cash Flow | $-188,000 | $-337,000 | $-58,000 | $-287,000 | $-298,000 |
| Exchange Rate Effect | -12,000 | -3,000 | -21,000 | -10,000 | -2,000 |
| Beginning Cash Position | 205,000 | 270,000 | 426,000 | 323,000 | 442,000 |
| End Cash Position | 188,000 | 205,000 | 270,000 | 426,000 | 323,000 |
| Net Cash Flow | $-5,000 | $67,000 | $-135,000 | $113,000 | $-117,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 564,000 | 737,000 | 530,000 | 638,000 | 464,000 |
| Capital Expenditure | -235,000 | -204,000 | -225,000 | -229,000 | -224,000 |
| Free Cash Flow | 329,000 | 533,000 | 305,000 | 409,000 | 240,000 |